Evidence map›Paper›PMID 28390972›Full record

ArticleVirus research2017

Targeting cell surface HIV-1 Env protein to suppress infectious virus formation.

Arangassery Rosemary Bastian, Charles G Ang, Kantharaju Kamanna, Farida Shaheen, Yu-Hung Huang, Karyn McFadden, Caitlin Duffy, Lauren D Bailey, Ramalingam Venkat Kalyana Sundaram, Irwin Chaiken

Open access · greenAbstract read
In one paragraph

Article in Virus research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Arangassery Rosemary BastianBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States; School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA 19104, United States. Electronic address: bastian.rosemary@gmail.com.
Charles G AngBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States; School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA 19104, United States.
Kantharaju KamannaBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States.
Farida ShaheenViral and Molecular Core, Penn Center for AIDS Research, University of Pennsylvania, Philadelphia, PA 19104, United States.
Yu-Hung HuangBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States.
Karyn McFaddenBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States.
Caitlin DuffyBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States.
Lauren D BaileyBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States.
Ramalingam Venkat Kalyana SundaramBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States; School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA 19104, United States.
Irwin ChaikenBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States. Electronic address: ichaiken@drexelmed.edu.
Drexel University · USUniversity of Pennsylvania · US

Funding

Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CAMERON F · 1997 to 2018
$31.2M
Multivalent Env gp120 Targeting Gold Nanoparticle Virucides of HIV-1R01GM111029 · NIGMS · DREXEL UNIVERSITY · PI CHAIKEN, IRWIN M · 2013 to 2016
$1.2M
NIGMS NIH HHS P01 GM056550NIGMS NIH HHS R01 GM111029
6 · The paper itself

Abstract

HIV-1 Env protein is essential for host cell entry, and targeting Env remains an important antiretroviral strategy. We previously found that a peptide triazole thiol KR13 and its gold nanoparticle conjugate AuNP-KR13 directly and irreversibly inactivate the virus by targeting the Env protein, leading to virus gp120 shedding, membrane disruption and p24 capsid protein release. Here, we examined the consequences of targeting cell-surface Env with the virus inactivators. We found that both agents led to formation of non-infectious virus from transiently transfected HEK293T cells. The budded non-infectious viruses lacked Env gp120 but contained gp41. Importantly, budded virions also retained the capsid protein p24, in stark contrast to p24 leakage from viruses directly treated by these agents and arguing that the agents led to deformed viruses by transforming the cells at a stage before virus budding. We found that the Env inactivators caused gp120 shedding from the transiently transfected HEK293T cells as well as non-producer CHO-K1-gp160 cells. Additionally, AuNP-KR13 was cytotoxic against the virus-producing HEK293T and CHO-K1-gp160 cells, but not untransfected HEK293T or unmodified CHO-K1 cells. The results obtained reinforce the argument that cell-surface HIV-1 Env is metastable, as on virus particles, and provides a conformationally vulnerable target for virus suppression and infectious cell inactivation.

Indexed as

Virus InactivationAnimalsAntiviral AgentsCHO CellsCricetulusenv Gene Products, Human Immunodeficiency VirusHEK293 CellsHIV-1HumansPeptidesTriazolesVirus AssemblyAntiviral Agentsenv Gene Products, Human Immunodeficiency VirusPeptidesTriazolesGold nanoparticlesHIV-1Infected cell inactivationMultivalencyPeptide triazoles

Identifiers

PMID28390972
PMCPMC5555212
OpenAlexW2604564910

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.